GSK2334470
Names
[ CAS No. ]:
1227911-45-6
[ Name ]:
GSK2334470
[Synonym ]:
(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide
CS-0917
3-Piperidinecarboxamide, 1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-, (3S,6R)-
QC-8425
GSK2334470
Biological Activity
[Description]:
[Related Catalog]:
[Target]
IC50: 10 nM(PDK1)[1]
[In Vitro]
[In Vivo]
[Cell Assay]
[Animal admin]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Molecular Formula ]:
C25H34N8O
[ Molecular Weight ]:
462.591
[ Exact Mass ]:
462.285553
[ PSA ]:
132.30000
[ LogP ]:
2.31
[ Appearance of Characters ]:
white to light brown
[ Index of Refraction ]:
1.667
[ Storage condition ]:
2-8°C
[ Water Solubility ]:
DMSO: ≥10mg/mL
MSDS
Safety Information
[ RIDADR ]:
NONH for all modes of transport
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Oncotarget 6(7) , 5134-46, (2015)
Dual PI3K/mTOR(phosphatidylinositol 3-kinase/mammalian target of rapamycin) inhibitors are being evaluated clinically for the treatment of tumors with a hyperactivated PI3K/mTOR pathway. However, unex...
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.Breast Cancer Res. 18 , 41, (2016)
The PI3K pathway is hyperactivated in many cancers, including 70 % of breast cancers. Pan- and isoform-specific inhibitors of the PI3K pathway are currently being evaluated in clinical trials. However...
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.Oncotarget 5(10) , 3145-58, (2014)
Our understanding of breast cancer heterogeneity at the protein level is limited despite proteins being the ultimate effectors of cellular functions. We investigated the heterogeneity of breast cancer...